GlassScriptPhysician profile
Doris M Ponce
NPI 1114192242
$153,506.09
in general payments reported to CMS, 2019-2025
14 companies · $47K in 2025
The $47K reported for 2025 was more than what 96% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $55.52 · 2020: $4,955 · 2021: $240 · 2022: $31K · 2023: $42K · 2024: $29K · 2025: $47K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $68K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $38K · Travel and Lodging: $7,584 · Food and Beverage: $3,655.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $68,184.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $37,596.00 |
| Travel and Lodging | $7,584.08 |
| Food and Beverage | $3,655.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $97,504.77 | 2022-2025 | Jakafi, Niktimvo |
| Sanofi-Aventis U.S. LLC | $29,222.30 | 2022-2025 | |
| Sanofi Pasteur INC. | $19,114.55 | 2025 | |
| Kadmon Pharmaceuticals LLC | $4,037.96 | 2019-2021 | |
| Csl Behring | $1,000.00 | 2020 | |
| Genzyme Corporation | $814.15 | 2025 | |
| National Marrow Donor Program | $539.42 | 2024-2025 | |
| Zoll Medical Corporation | $520.00 | 2024 | Defibrillator |
| Eurofins Viracor, LLC | $212.34 | 2021 | |
| Sobi, INC | $204.65 | 2025 | |
| Jazz Pharmaceuticals INC. | $143.43 | 2024 | |
| Seres Therapeutics, INC. | $119.92 | 2023-2024 | Vowst |
| Takeda Pharmaceuticals U.S.A., INC. | $72.60 | 2024 | Ninlaro |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Doris Ponce listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.